Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.

David A Cameron Vikash Kumar Sharma Chandroday BiswasCathy ClarkeDavid ChandiwanaPurnima Pathak

Published in: Journal of medical economics (2023)

Ribociclib is both cost-saving and cost-effective compared with palbociclib for the 1L treatment of postmenopausal women with HR+/HER2- ABC in the UK.

Keyphrases

bone mineral density
breast cancer risk
metastatic breast cancer
combination therapy
young adults
replacement therapy
smoking cessation